top of page

Arthritis drug reduces rates of acute graft-vs-host disease after bone marrow transplant

​Exciting news from a Phase 2 trial led by Leslie Kean (Dana-Farber/Boston Children’s), published Friday in the Journal of Clinical Oncology. A repurposed rheumatology drug, abatacept, reduced the risk of severe, acute graft-vs.-host disease after bone marrow transplant and improved GVHD-free survival. The drug was especially beneficial in patients with an imperfect donor match (on just 7 of 8 HLA factors).


0 views0 comments
bottom of page